Soleno

Soleno developed a once-daily oral tablet, diazoxide choline, for the treatment of Prader-Willi Syndrome which achieved FDA approval in March 2025. Previously, no therapies were approved to treat this rare genetic condition, which causes chronic insatiable hunger as well as behavioural problems, cognitive disabilities, low muscle tone and short stature. The product has orphan drug designation in the US and Europe. Soleno was a VIPE (Venture Investment in Public Equity) and in May 2026 was acquired by Neurocrine for a total transaction equity value of $2.9 billion.